The Meals and Drug Administration evaluates medication for security and efficacy, however now the Facilities for Medicare and Medicaid Providers desires to behave as a political test on the FDA’s choices. Final week CMS refused to cowl a novel Alzheimer’s remedy for thousands and thousands of sufferers as a result of it disagreed with FDA approval.
Biogen ’s Aduhelm is the primary FDA-approved remedy proven to sluggish the development of Alzheimer’s. However the drug is now ensnared in a political combat. The general public-health left thinks FDA is approving too many new costly medication with marginal advantages, and it desires CMS to overrule the drug company. Progressives are cheering CMS’s Aduhelm resolution as a precedent that the company can prohibit entry to new FDA-approved remedies. Aduhelm is the goal at this time, however most cancers and gene therapies may very well be subsequent.
